ArticleBMC immunology2026
Correlation analysis of positive Alzheimer's disease plasma biological markers with plasma immune cell and clinical characteristics in mild cognitive impairment patients in China.
Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThe aim of the present work was to investigate the correlation between positive Alzheimer's disease (AD) plasma biological markers and plasma immune cell content as well as clinical characteristics in mild cognitive impairment (MCI) patients.
methodsA total of 176 patients aged ≥ 65 years with MCI were followed up for two years. At baseline, AD plasma biomarkers (Aβ42, Aβ40, Aβ42/40, P-tau181 and PTau217) and immune cells (Treg cells, TH17 cells, lymphocytes) in MCI patients were detected, and their relevant clinical characteristics were recorded. Finally, the correlation between positive AD plasma biomarkers and immune cells, relevant clinical characteristics of MCI patients, and whether they would progress was analyzed.
resultsPlasma Aβ42/40 levels are negatively correlated with age, a history of hypertension, constipation symptoms, and the TGF-β/Treg cell ratio. They are positively correlated with the TIM3+/Treg cell ratio, the number of CD19-positive cells, the CD4/CD8 ratio, and the number of CD8-positive cells. Plasma PTau217 levels are positively correlated with age, the proportion of B cells, and the proportion of NK cells, and negatively correlated with visual-spatial executive function and attention cognitive domain scores. Dual abnormalities of Aβ42/40 and PTau217 are positively correlated with age and the proportion of B cells, and negatively correlated with cognitive domain scores for executive ability, attention, and language ability.
conclusionAbnormalities in AD plasma biomarkers are associated with immune activation (particularly B cells and NK cells), aging, cardiovascular and gastrointestinal risk factors, and cognitive decline. The concurrent abnormalities of multiple biomarkers may exacerbate these associations, although some immune regulatory pathways do not show significant effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.